GRAIL’s $900 Million in First Close of Series B Financing

Fenwick & West represented GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, in raising over $900 million through the first close of its Series B financing.

The financing was led by ARCH Venture Partners and includes Johnson & Johnson Innovation as the largest investor in the financing. Other strategic investors participating in the financing include Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck, Tencent Holdings Limited and Varian Medical Systems, Inc. GRAIL will use the funds to support continued product development and validation of blood tests for early-stage cancer detection.

The Fenwick transaction team was led by corporate lawyers Gordy Davidson (Picture), Matthew Rossiter, Jordan Koss, Brendan Franich, Elizabeth Federowicz, Bryce Daigle and Kyle Canchola; antitrust lawyers Mark Ostrau and Ashley Walter; and tax lawyer Will Skinner.

Involved fees earner: Gordon Davidson – Fenwick & West LLP; Matthew Rossiter – Fenwick & West LLP; Jordan Koss – Fenwick & West LLP; Brendan Franich – Fenwick & West LLP; Elizabeth Federowicz – Fenwick & West LLP; Bryce Daigle – Fenwick & West LLP; Kyle Canchola – Fenwick & West LLP; Mark Ostrau – Fenwick & West LLP; Ashley Walter – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Grail Inc.;

Print Friendly, PDF & Email

Author: Ambrogio Visconti